Q-omics provides the consensus-scored ZNF227 profile across patient tissues and cancer cell-line models. ZNF227 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ZNF227 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, ZNF227 RNA expression shows 21,872 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight MESO, HNSC, and KIRP as cancer lineages where ZNF227 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF227 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF227 survival associations across molecular data types. ZNF227 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF227 RNA expression–survival associations across cancer types. High ZNF227 expression shows unfavorable associations in MESO, LGG, KIRP and LUSC, but favorable associations in KIRC and GBM. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ZNF227 RNA expression.
This table summarizes ZNF227 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF227. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF227 shows lower tumor expression in THCA and higher tumor expression in HNSC, BLCA, LIHC, KIRC and CHOL. The HNSC box plot shows higher ZNF227 RNA expression in tumor versus normal tissue (log2 FC = +0.612, t-test p < 0.001).
This table shows molecular features associated with ZNF227 in patient tissues and cancer cell lines. In patient samples, ZNF227 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF227 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
